Bristol-Myers Squibb Company (BMY)
Pharmaceutical Preparations · market cap $126.6B · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
- 2026-12-15 (est.)Phase 2 · Elotuzumabimp 7/10
- 2026-12-20 (est.)Phase 2 · Nivolumabimp 7/10
- 2026-12-30 (est.)Phase 2 · Ipilimumabimp 7/10
- 2026-12-31 (est.)Phase 3imp 7/10
- 2026-12-31 (est.)Phase 2 · Nivolumab inimp 7/10
- 2027-01-01Otherimp 4/10
- 2027-01-15 (est.)Phase 2 · Nivolumabimp 7/10
- 2027-02-05 (est.)Phase 2 · Nivolumabimp 7/10
| Asset | Phase | Indication |
|---|---|---|
| Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma |
| CC-97540 | Phase 2 | Lupus Erythematosus, Systemic |
| MDX-010/MDX-010 + Docetaxel | Phase 2 | Prostate Cancer |
| Drugs Nivolumab | Phase 2 | Renal Cell Carcinoma, Clear Cell |
| BMS-986213 (Relatlimab-Nivolumab FDC) | Phase 2 | Renal Cell Carcinoma, Clear Cell |
| Nivolumab, Surgery, Radiotherapy | Phase 2 | Squamous Cell Carcinoma of the Oral Cavity |
| SOX | Phase 2 | Gastric Cancer |
| Relatlimab + Nivolumab | Phase 2 | Melanoma |
| Vinflunine | Phase 3 | Bladder Cancer |
| Nivolumab, Surgery, Chemoradiotherapy | Phase 2 | Squamous Cell Carcinoma of the Oral Cavity |
| cabiralizumab | Phase 2 | Peripheral T Cell Lymphoma |
| BMS-650032 (NS3 Protease Inhibitor) | Phase 2 | Hepatitis C |
| Belatacept More Intensive Regimen (MI) | Phase 3 | Renal Transplantation |
| Belatacept Less Intensive Regimen (LI) | Phase 3 | Renal Transplantation |
| Combination of varlilumab and nivolumab | Phase 2 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| MDX-1379 (gp100) Melanoma Peptide Vaccine | Phase 3 | Melanoma |
| Nivolumab & Ipilimumab | Phase 2 | Prostate Cancer |
| Galunisertib | Phase 2 | Solid Tumor |
| Pegylated Interferon Lambda (pegIFNλ) | Phase 2 | Hepatitis C |
| PegIFN lambda | Phase 2 | Hepatitis B Virus |
Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for BMY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
